Treatment of Dyrk1A-dependent Mental Retardation of Down Syndrome: Isolation of Human Dyrk1A-specific shRNA

Min-Su Jung, Yeun-Soo Kim, Juhyun Kim1, Jong-Hun Kim1, Sul-Hee Chung and Woo-Joo Song*

Institute for Brain Science and Technology (IBST), Graduate Program in Neuroscience, Inje University, Busan, 614-735, Korea

1Department of Life Science, Pohang University of Science and Technology, Pohang, Kyungbuk, 790-784, Korea

Received December 4, 2008 /Accepted March 3, 2009

Down syndrome (DS) results from overexpressed genes on an extra copy of human chromosome 21. Among various phenotypes seen in DS patients, mental retardation, such as learning and memory deficits, is a major factor that prevents DS individuals from leading fully independent lives. The Dyrk1A gene that plays a critical role in neurodevelopment has been isolated from chromosome 21, and transgenic mice with over-expression of Dyrk1A show severe hippocampal dependent learning and memory defects. In the present study, as an initial step to test the treatment of Dyrk1A dependent mental retardation phenotypes in model animals, we isolated human Dyrk1A specific lentiviral short hairpin RNA (shRNA) that inhibits the exogenous human Dyrk1A expression, but not the endogenous mouse expression in transgenic mice with human Dyrk1A overexpression. This limited and specific repression of exogenous human Dyrk1A will prove to be valuable information, if Dyrk1A dependent learning and memory defects in DS patients could be treated or at least ameliorated in vivo.

Key words: Down syndrome, Dyrk1A, mental retardation, RNA interference, lentivirus

Introduction

With a frequency of one in roughly every 800 births, Down syndrome (DS) is the most common genetic anomaly and results from the presence of an extra copy of human chromosome 21 [9,12]. In addition to characteristic physical features, individuals with DS show a variety of phenotypes, such as low muscle tone, congenital heart defects, immune defects, a high incidence of leukemia, and early onset of Alzheimer-like dementia [11,14,15]. DS patients also suffer from mental retardation, which is a major factor preventing them from leading fully independent lives in their early to middle-age years. As a result of the search for the responsible gene(s), the Dyrk1A gene, which plays a critical role in neurodevelopment, was isolated from chromosome 21 [5,10,19,21]. Dyrk1A is a member of the Dyrk [dual-specificity Tyrosine regulated kinase] family, and has dual substrate specificities: tyrosine-321 residue autophosphorylation for self-activation and serine/threonine kinase [10,13]. Transgenic (Tg) mice overexpressing human or mouse Dyrk1A show learning and memory defects [1,2,20]. Previously, the authors of this study reported the production of transgenic mice, Dyrk1A BAC Tg, using a bacterial artificial chromosome (BAC) clone that contained the complete human Dyrk1A genome including the endogenous promoter [1]. These Dyrk1A BAC Tg mice overexpressed human Dyrk1A and showed severe learning and memory deficiencies, indicating that Dyrk1A is strongly associated with the mental retardation seen in DS. At present, no therapy is available to treat the mental retardation associated with DS.

In 1995, during attempts to repress a specific gene expression using antisense RNA in the maternal germ line, RNA interference (RNAi) was unexpectedly discovered [3,6]. RNAi refers to the sequence-specific target cellular or viral RNA degradation process [16,18]. This phenomenon has been observed in a wide variety of organisms, including plants, worms, flies, and vertebrates, and has emerged as a powerful technique for studying the function of proteins and in treating various diseases [4,7,22]. For gene therapy purposes, the lentiviral system is considered the suitable RNAi delivery method, since lentivirus has proved useful for efficient transduction into various cells as well as for long-term expression and for infection into non-dividing cells.

In this study, a recombinant lentivirus expressing a human Dyrk1A-specific short hairpin RNA (shRNA) is isolated to be used in testing potential treatment of learning and memory deficiencies observed in human Dyrk1A overexpressing transgenic mice. The human Dyrk1A specific
shRNA will specifically repress the exogenous human Dyrk1A of transgenic mice overexpressing human Dyrk1A while the endogenous mouse Dyrk1A is normally expressed. This viral shRNA could be a valuable resource in testing the potential for reversal of learning and memory deficiencies seen in Dyrk1A transgenic mice and DS patients.

Materials and Methods

Plasmid constructs

Mouse 763 amino acid full-length Dyrk1A cDNA was cloned into the mammalian expression vector pcDNA3.1 as previously described [21]. The human 754 amino acid Dyrk1A cDNA in pcDNA3.1 was kindly provided by Dr. de la Luna. siRNAs that specifically inhibit the expression of human Dyrk1A were cloned into pLentiLox3.7 virus vector for viral production [17]. The construction of the recombinant vector was executed as follows: the sense sequence consisted of the selected siRNA sequence followed by a TTCAAGAGA loop, the reverse complementary sequence, and 6 Thymidines with restriction sites of HpaI and XhoI at 5' and 3', respectively. The sense and complementary antisense oligos were synthesized and annealed for cloning into the HpaI and XhoI sites of the pLentiLox3.7 vector.

siRNA transfection and Western analysis

Sixty pmole of synthesized duplex siRNA with TT overhang was cotransfected with human or mouse Dyrk1A clone into human embryonic kidney (HEK293T) cells in 6-well plates (seeded at a density of 7 × 10^5 cells/well one day earlier) using Lipofectamine 2000. FITC conjugated GFP specific vector was used as a transfection control. One day after siRNA transfection and Western analysis

Viral production and transduction

A three-plasmid system was used to produce the human Dyrk1A-specific shRNA expressing lentivirus. The system consists of the packaging, envelope and shRNA-expressing vector, and allows the production of a self-replication-independent virus for safe manipulation. One day before transfection, HEK293T cells were seeded on one day, and the following day the cells were infected with virus. Six hr later the medium was changed and cells were further incubated for 24 hr. The next day, the human or mouse Dyrk1A clone was transfected as previously described. 36 ~ 48 hr after transfection, cells were harvested and the cell lysates were prepared for Western analysis.

Results

Selection of human Dyrk1A-specific siRNA

Several small interfering RNA (siRNA) design programs including siRNA wizard were used to select the candidate siRNAs, which consisted of 18 ~ 25 nucleotide long human Dyrk1A. The sequence was then compared with the mouse Dyrk1A sequence (93% identity at the nucleotide level), and 10 human Dyrk1A siRNAs with 2 ~ 5 nucleotides different from those of the mouse sequence (Table 1) were selected. Each synthesized siRNA was cotransfected with the mouse or human Dyrk1A clone into HEK293T. One day after transfection, cell lysates were subjected to Western analysis to determine whether each siRNA inhibits the expression of human and/or mouse Dyrk1A. Fig. 1 shows representative blots of screening for human-specific siRNA isolations. siRNAs #1 and #2 showed a very strong and a moderate inhibition on the human Dyrk1A expression, respectively, while siRNA #3 showed a minimal repression for the human Dyrk1A expression. None of the three siRNAs (#1, #2 or #3) significantly inhibited the expression of the mouse Dyrk1A.

Table 1. DNA sequences of selected 10 human Dyrk1A siRNAs

<table>
<thead>
<tr>
<th>siRNA</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>5-TCTATGACGTGCTGAGA-3 (2)</td>
</tr>
<tr>
<td>#2</td>
<td>5-GTTCGGCTTGACCGTCATTT-3</td>
</tr>
<tr>
<td>#3</td>
<td>5-GTTCGCTCTAATCACTTCT-3 (2)</td>
</tr>
<tr>
<td>#4</td>
<td>5-GTACATGTCAGCGCTAGGT-3</td>
</tr>
<tr>
<td>#5</td>
<td>5-GCAAGCATAAAGTACGCC-3 (2)</td>
</tr>
<tr>
<td>#6</td>
<td>5-GAGAGAGATCTAGTCATAAG-3 (2)</td>
</tr>
<tr>
<td>#7</td>
<td>5-ACGCATATTGAGTGCG-3 (5)</td>
</tr>
<tr>
<td>#8</td>
<td>5-GAGTCAGGTACAGTCGCCT-3 (4)</td>
</tr>
<tr>
<td>#9</td>
<td>5-AACAGGTTCTGCTCCTATCA-3</td>
</tr>
<tr>
<td>#10</td>
<td>5-GATAGTGAATTTGACGCACT-3</td>
</tr>
</tbody>
</table>

1The mismatched human Dyrk1A nucleotide sequences different from the mouse sequences are underlined, and number of mismatch is shown in parenthesis.
Fig. 1. Screening of siRNAs. The indicated siRNA was cotransfected with human (A) or mouse (B) Dyrk1A-expressing plasmid into HEK293T cells. Cell lysate (50 μg) was subjected to Western blotting to analyze the Dyrk1A repression. Non-specific GFP siRNA was used as a transfection negative control and a control siRNA with a common sequence for both human and mouse Dyrk1A was used a positive control.

#3) inhibited the expression of the mouse Dyrk1A. From 10 siRNAs tested, siRNAs #1 and #9 were identified as having specific inhibitory activity on the expression of human Dyrk1A, but not on mouse Dyrk1A (Fig. 2). These two siRNA sequences were used for the construction of recombinant viral vectors that express shRNA to test the human Dyrk1A-specific inhibition.

shRNA lentivirus production

For long-term exogenous human Dyrk1A gene repression and for infection into non-dividing neuronal cells of Dyrk1A BAC Tg mice, two siRNAs (#1 and #9) with specific repression activity for human Dyrk1A expression were cloned into lentiviral vectors for virus production expressing shRNA. Expression of Green Fluorescent Protein (GFP) under the control of a CMV promoter was used as an indication of shRNA expression. A three-vector system was used to produce the recombinant lentivirus. The recombinant pLentiLox3.7 clone was cotransfected with the plasmid expressing gag and pol genes into HEK293T cells for viral production. The production of virus was estimated by observing the intensity of the GFP signal under a fluorescent microscope (Fig. 3). A virus titer of $10^6 ~-~ 10^7$ cfu/ml was used for infection.

Isolation of the human-specific shRNA expressing lentivirus

The following procedures were taken to check the repression of Dyrk1A expression by viral infection. To allow sufficient time for viral shRNA expression, HEK293T cells were first treated with virus. Then next day, the infected cells were transiently transfected with the human or mouse Dyrk1A for exogenous expression. The following day, a good expression of GFP was routinely observed, indicating good infection and expression of shRNA. The cell lysates were tested for Dyrk1A expression. As expected from the siRNA treatment, neither treatment with viral shRNA #1 nor treatment with viral shRNA #9 inhibited the expression of mouse Dyrk1A. Treatment with shRNA #9 was found to strongly repress the expression of human Dyrk1A, while shRNA #1 had a little effect (Fig. 4). In conclusion, a human
Dyrk1A-specific shRNA expressing lentivirus required for in vivo study in evaluating the treatment of mental retardation of Dyrk1A BAC Tg mice was isolated in this study.

Discussion

DS is caused by the duplication of human chromosome 21. Since the genome size of chromosome 21 is larger than 33 Mb and the genome contains about 300 genes [8], it is overwhelming to pinpoint the individual genes responsible for each phenotype of DS, and it is an even more daunting task to try to treat those phenotypes. Among the many phenotypes of DS, mental retardation is the most devastating impediment to patients with DS being able to lead independent lives. Thus far, there is no therapeutic drug available for the treatment of the mental retardation associated with DS. In 1996, several research teams reported the isolation of the Dyrk1A gene [5,10,19,21], and produced Dyrk1A transgenic mice with learning and memory defects, opening a door for a potential therapeutic approach [1,2,20]. Dyrk1A BAC Tg mice produced in the laboratory of this study carry one extra copy of the human Dyrk1A genome in addition to the endogenous two mouse Dyrk1A copies, and showed severe learning and memory deficits. Such mice provide a unique tool for testing whether the specific repression of extra human Dyrk1A could reverse the mental retardation seen in this model animal. As an initial step toward conducting such testing, this study reports the isolation of a human specific Dyrk1A shRNA lentivirus that specifically inhibits the exogenous human Dyrk1A expression, but not the endogenous mouse one. Successful targeting of the isolated shRNA into affected brain areas, such as the hippocampus, and analysis would provide a valuable next step in developing therapeutic interventions in the future.

Acknowledgments

This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (R01-2007-000-11910-0 to W.J.S.). This work was also supported by the Korea Research Foundation Grant funded by the Korean Government (KRF-2007-331-E00031 to W.J.S. and KRF-2008-314-E00180 to W.J.S.).

References

초록: 다운증후군의 Dyrik1A의 조작적 뇌기능저하의 치료: 인간 Dyrik1A의 특이적 shRNA 발굴

정민수, 김인수, 김주현, 정설희, 송우주* (인제대학교 뇌과학기술연구소, 포항공과대학교 생명과학과)

다운증후군은 추가적으로 존재하는 인간염색체 21번에 위치한 유전자 발현으로 발생한다. 다운증후군 환자에서 보이는 여러 증상들 중 학습과 기억능력 저하와 같은 뇌기능 저하는 다운증후군 환자가 독립적인 생활을 영위하는데 가장 큰 걸림돌이 된다. 다운증후군은 이러한 증상들의 회복 가능성을 찾기 위한 치료법을 개발하는데 많은 연구가 이루어지고 있다. 본 연구에서는 인간 Dyrik1A를 조작하여 형질전환 생쥐를 만드는 방법을 이용하여 다운증후군 환자에서의 뇌 기능 저하를 치료할 수 있는 치료제 개발을 위해 인간 Dyrik1A의 조작적 shRNA을 발굴하였다. 발현된 shRNA는 인간 Dyrik1A의 발현을 조작하여 다운증후군 환자의 뇌 기능 저하를 개선하는 치료제 개발을 위한 중요한 정보를 제공할 것이다.